Atheroembolic renal disease: Analysis of clinical and therapeutic factors that influence its progression;Enfermedad renal ateroembólica: Un análisis de los factores clínicos y terapéuticos que influyen en su evolución

Nefrologia

Volumn 30, Issue 3, 2010, Pages 317-323

  Gutierrez Solis E ^a   Morales, E ^a   Rodriguez Jornet A ^b   Andreu, F J ^b   Rivera, F ^c   Vozmediano, C ^c   Gutierrez E ^a   Igarzabal A ^a   Enguita, A B ^a   Praga, M ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL DE SABADELL   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE CIUDAD REAL   (Spain)

Author keywords

Acute renal failure; Cholesterol; Embolism; Steroids

Indexed keywords

ANTICOAGULANT AGENT; CORTICOSTEROID; CREATININE;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANGIOGRAPHY; AORTA DISEASE; ARTICLE; ATHEROSCLEROSIS; BLOOD; CATHETERIZATION; CLINICAL TRIAL; COMORBIDITY; CONVALESCENCE; DISEASE COURSE; EOSINOPHILIA; FAT EMBOLISM; FEMALE; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; MULTICENTER STUDY; RENAL REPLACEMENT THERAPY; RISK FACTOR; RUPTURE; SMOKING;

ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ANGIOGRAPHY; ANTICOAGULANTS; AORTIC DISEASES; ATHEROSCLEROSIS; CATHETERIZATION; COMORBIDITY; CREATININE; DISEASE PROGRESSION; EMBOLISM, CHOLESTEROL; EOSINOPHILIA; FEMALE; HUMANS; HYPERTENSION; KIDNEY FAILURE, ACUTE; MALE; MIDDLE AGED; RECOVERY OF FUNCTION; RENAL DIALYSIS; RISK FACTORS; RUPTURE, SPONTANEOUS; SMOKING;

EID: 77954630179     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2010.Apr.10367     Document Type: Article

References (19)

1. Modi KM, Rao EK. Atheroembolic renal disease. J Am Soc Nephro 2001;12:1781-7.
2. Thurlbeck VM, Castleman B. Atheromatous emboli to the kidney after aortic surgery. N Engl J Med 1957;257:442-7.
3. Scolari F, Tardanica R, Zani R, Pola A, Viola BF, Movilli E, et al. Cholesterol crystal embolism: a recognizable cause of renal disease AJKD 2000;36:1089-109.
4. Blankenship JC, Butler M, Garbes A. Prospective assessment of cholesterol embolization in patients with thrombolytic vs conservative therapy. Chest 1995;107:552-7.
5. Rodríguez Jornet A, Andreu FJ, Orellana R, Ibeas J, Vallvé M, Esteve V, et al. Diagnóstico y pronóstico de la enfermedad ateroembólica Nefrologia 2005;25(6):637-44.
6. Fine MJ, Kapoor W, Falanga V. Colesterol crystal embolization: a review of 221 cases in the English literature. Angiology 1987;38:769-84.
7. Belenfant X, Meyer A, Jacquot C. Supportive treatment improves survival in multivisceral cholesterol crystal embolism. Am J Kidney Dis 1999;33(5):840-50.
8. Scolari F, Ravani P, Gaggi R, Santosfefano M, Rollino C, Stabellini N, et al. The challenge of diagnosing atheroembolic renal disease: clinical features and prognostic factors. Circulation 2007;116:298-304.
9. Scoble JE, O'Donnell PJ. Renal atheroembolic disease: the Cinderella of nephrology? Nephrol Dial Transplant 1996;11(8):1516-7.
10. Wolfson RG, Lachmann H. Improvement in renal cholesterol emboli syndrome after simvastatin. Lancet 1998;351:1331.
11. Cabili S, Hochman I, Goor Y. Reversal of gangrenous lesions in the blue toe syndrome with lovastatin-a case report. Angiology 1993;44:821-25.
12. Nakayama M, Nagata M, Hirano T, Sugai K, Katafuchi R, Imayama S, et al. Low-dose prednisolone ameliorates acute renal failure caused by cholesterol crystal embolis. Clin Nephrol 2006;66(4):232-9.
13. Koga J, Ohno M, Okamoto K, Nakasuga K, Ito H, Nagafiji K, et al. Cholesterol embolization treated with corticosteroids: two case reports. Angilogy 2005;56:497-501.
14. Grenader T, Lifschitz M, Shavit L. Iloprost in embolic renal failure. Mt Sinai J Med 2005;72(5):339-41.
15. Sanai T, Matsui R, Hirano T. LDL apheresis for cholesterol embolism following coronary artery bypass graft surgery: a case report. Angiology 2006;57:379-82.
16. Tsunoda S, Daimon S, Miyazaki R, Fujii H, Inazu A, Mabuchi H. LDL apheresis as intensive lipid-lowering therapy for cholesterol embolism. NDT 1999;14:1041-2.
17. Górriz JL, Sancho A, Garcés R, Amorós F, Crespo JF, Pallardó LM. Recovery of renal function after renal failure due to cholesterol crysta embolism. Nephrol Dial Transplant 1999;14:2261.
18. Scolari F, Ravani P, Pola A, Guerini S, Zubani R, Movilli E, et al. Predictors of renal and patients outcomes in atheroembolic renal disease: a prospective study. J Am Soc Nephro 2003;14:1584-90
19. Martín-Ventura JL, Blanco-Colio LM, Gómez-Hernández A, Mu-ñoz-García B, Vega M, Serrano J, et al. Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atheroesclerotic lesions in one month. Stroke 2005;36:1796-800.